World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
65
Citations
24935
World Ranking
2802
National Ranking
1323

Terry J. Fry publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Terry J. Fry sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 295 publications — 63rd percentile

63% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Terry J. Fry D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Terry J. Fry sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 65 D-Index — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Terry J. Fry is affiliated with the University of Colorado Denver in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a substantial focus on Oncology, Molecular Biology, Immunology, and Genetics as subfields.

The main topics of their work include:

  • CAR-T cell therapy research
  • Viral Infectious Diseases and Gene Expression in Insects
  • Virus-based gene therapy research
  • Immune Cell Function and Interaction
  • Acute Lymphoblastic Leukemia research
  • Immunotherapy and Immune Responses
  • CRISPR and Genetic Engineering

Notable recent papers authored or co-authored by Terry J. Fry include:

  • "CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial" (2021) published in Nature Medicine
  • "CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial" (2020) published in Journal of Clinical Oncology
  • "Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL" (2021) published in Journal of Clinical Oncology
  • "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events" (2020) published in Journal for ImmunoTherapy of Cancer
  • "Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells" (2021) published in Blood

Frequent co-authors collaborating with Terry J. Fry are:

  • Nirali N. Shah
  • M. Eric Kohler
  • Bonnie Yates
  • Haneen Shalabi
  • Aaron E. Foster

Terry J. Fry has contributed extensively to multiple prominent scientific journals. Their most frequent publication venues include:

  • Blood
  • Cancer Research
  • Journal for ImmunoTherapy of Cancer
  • Neuro-Oncology
  • Journal of Clinical Oncology

The body of work by Terry J. Fry reflects a strong focus on CAR-T cell therapy, emphasizing research on therapy potency, toxicity, and long-term outcomes. Their studies also address the clinical management of immune effector cell-related adverse events and manifestations resembling hemophagocytic lymphohistiocytosis (HLH) in the context of CAR T cell treatments.

Best Publications

  • T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

    Daniel W Lee;James N Kochenderfer;Maryalice Stetler-Stevenson;Yongzhi K Cui

  • 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

    Adrienne H Long;Waleed M Haso;Jack F Shern;Kelsey M Wanhainen

  • CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.

    Terry J Fry;Nirali N Shah;Rimas J Orentas;Maryalice Stetler-Stevenson

  • Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

    Elena Sotillo;David M. Barrett;Kathryn L. Black;Asen Bagashev

  • Mechanisms of resistance to CAR T cell therapy

    Nirali N. Shah;Terry J. Fry

  • The Many Faces of IL-7: From Lymphopoiesis to Peripheral T Cell Maintenance

    Terry J. Fry;Crystal L. Mackall

  • Harnessing the biology of IL-7 for therapeutic application

    Crystal L. Mackall;Terry J. Fry;Ronald E. Gress

  • Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

    Marco Ruella;Jun Xu;David M. Barrett;Joseph A. Fraietta

  • Interleukin-7: from bench to clinic.

    Terry J. Fry;Crystal L. Mackall

  • Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets

    Claude Sportès;Frances T. Hakim;Sarfraz A. Memon;Hua Zhang

  • CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

    Jay Y. Spiegel;Shabnum Patel;Lori Muffly;Nasheed M. Hossain

  • IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells.

    Steven A. Rosenberg;Claude Sportès;Mojgan Ahmadzadeh;Terry J. Fry

  • A potential role for interleukin-7 in T-cell homeostasis

    Terry J. Fry;Elizabeth Connick;Judith Falloon;Michael Marcel Lederman

  • CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity

    Elad Jacoby;Sang M. Nguyen;Thomas J. Fountaine;Kathryn Welp

  • CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

    Nirali N. Shah;Steven L. Highfill;Haneen Shalabi;Bonnie Yates

  • Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies.

    Marianna Sabatino;Jinhui Hu;Michele Sommariva;Michele Sommariva;Sanjivan Gautam

  • Interleukin-7: master regulator of peripheral T-cell homeostasis?

    Terry J. Fry;Crystal L. Mackall

  • IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation

    Crystal L. Mackall;Terry J. Fry;Cathy Bare;Paul Morgan

  • Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase

    Alec J. Walker;Robbie G. Majzner;Ling Zhang;Kelsey Wanhainen

  • Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL.

    Nirali N Shah;Daniel W Lee;Bonnie Yates;Constance M Yuan

  • A Role for Thymic Stromal Lymphopoietin in CD4+ T Cell Development

    Amin Al-Shami;Rosanne Spolski;John Kelly;Terry Fry

Frequent Co-Authors

Crystal L. Mackall
Crystal L. Mackall Stanford University
Maryalice Stetler-Stevenson
Maryalice Stetler-Stevenson National Institutes of Health
Ronald E. Gress
Ronald E. Gress National Institutes of Health
David F. Stroncek
David F. Stroncek National Institutes of Health
Seth M. Steinberg
Seth M. Steinberg National Institutes of Health
Rimas J. Orentas
Rimas J. Orentas University of Washington
James N. Kochenderfer
James N. Kochenderfer National Institutes of Health
Peter D. Aplan
Peter D. Aplan National Institutes of Health
David F. Stroncek
David F. Stroncek National Institutes of Health
Stephan A. Grupp
Stephan A. Grupp Children's Hospital of Philadelphia

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in immunology, exploring related healthcare degrees can open diverse career opportunities. Many students consider accelerated paths, such as an accelerated NP program, which offers a fast track to becoming a nurse practitioner while gaining specialized skills relevant to immunology-related healthcare settings.

Nurses aiming to specialize further might explore acute care programs. Transitioning to more specialized roles is possible through acnp programs, which prepare nurse practitioners to work with critically ill patients—often requiring a solid understanding of immunological responses.

Certificate programs offer additional flexibility, especially for those already in nursing roles. Finding affordable options like the cheapest pmhnp certificate programs allows for cost-effective career advancement while specializing in specific nursing fields linked to immunology.

Understanding compensation is also crucial when selecting a career path. Data such as dnp salary transparency helps students and professionals make informed decisions about their investments and future prospects in roles related to immunology and advanced nursing practice.

Best Scientists Citing Terry J. Fry

Trending Scientists

Recently Published Articles